108 related articles for article (PubMed ID: 7790175)
1. Hemophilia home treatment. Economic analysis and implications for health policy.
Ross-Degnan D; Soumerai SB; Avorn J; Bohn RL; Bright R; Aledort LM
Int J Technol Assess Health Care; 1995; 11(2):327-44. PubMed ID: 7790175
[TBL] [Abstract][Full Text] [Related]
2. Prophylactic use of factor VIII: an economic evaluation.
Bohn RL; Avorn J; Glynn RJ; Choodnovskiy I; Haschemeyer R; Aledort LM
Thromb Haemost; 1998 May; 79(5):932-7. PubMed ID: 9609224
[TBL] [Abstract][Full Text] [Related]
3. Episodic versus prophylactic infusions for hemophilia A: a cost-effectiveness analysis.
Smith PS; Teutsch SM; Shaffer PA; Rolka H; Evatt B
J Pediatr; 1996 Sep; 129(3):424-31. PubMed ID: 8804333
[TBL] [Abstract][Full Text] [Related]
4. Economic issues in European self-sufficiency.
Szucs TD
Blood Coagul Fibrinolysis; 1994 Dec; 5 Suppl 4():S51-5. PubMed ID: 7795140
[TBL] [Abstract][Full Text] [Related]
5. Cost-utility analysis of Canadian tailored prophylaxis, primary prophylaxis and on-demand therapy in young children with severe haemophilia A.
Risebrough N; Oh P; Blanchette V; Curtin J; Hitzler J; Feldman BM
Haemophilia; 2008 Jul; 14(4):743-52. PubMed ID: 18422610
[TBL] [Abstract][Full Text] [Related]
6. Economic evaluation of major knee surgery with recombinant activated factor VII in hemophilia patients with high titer inhibitors and advanced knee arthropathy: exploratory results via literature-based modeling.
Ballal RD; Botteman MF; Foley I; Stephens JM; Wilke CT; Joshi AV
Curr Med Res Opin; 2008 Mar; 24(3):753-68. PubMed ID: 18234151
[TBL] [Abstract][Full Text] [Related]
7. Economic costs of hemophilia and the impact of prophylactic treatment on patient management.
Chen SL
Am J Manag Care; 2016 Apr; 22(5 Suppl):s126-33. PubMed ID: 27266809
[TBL] [Abstract][Full Text] [Related]
8. Future characteristics of bypassing agents to improve care of hemophilia inhibitor patients: an economic and health-related quality of life perspective.
Weatherall J; Barnes N; Brown C; Préaud E
Expert Rev Pharmacoecon Outcomes Res; 2011 Aug; 11(4):411-4. PubMed ID: 21831021
[TBL] [Abstract][Full Text] [Related]
9. Is haemophilia prophylaxis achievable in the context of self-sufficiency?
Nilsson IM
Blood Coagul Fibrinolysis; 1994 Dec; 5 Suppl 4():S71-5. PubMed ID: 7795143
[TBL] [Abstract][Full Text] [Related]
10. Current management of the hemophilic child: a demanding interlocutor. Quality of life and adequate cost-efficacy analysis.
Giordano P; Lassandro G; Valente M; Molinari AC; Ieranò P; Coppola A
Pediatr Hematol Oncol; 2014 Nov; 31(8):687-702. PubMed ID: 25006797
[TBL] [Abstract][Full Text] [Related]
11. Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.
CMAJ; 1995 Jul; 153(2):147-57. PubMed ID: 7600466
[TBL] [Abstract][Full Text] [Related]
12. Cost-utility analysis of life-long prophylaxis with recombinant factor VIIIFc vs recombinant factor VIII for the management of severe hemophilia A in Sweden.
Henry N; Jovanović J; Schlueter M; Kritikou P; Wilson K; Myrén KJ
J Med Econ; 2018 Apr; 21(4):318-325. PubMed ID: 29139314
[TBL] [Abstract][Full Text] [Related]
13. Haemophilia and home therapy.
Lancet; 1979 Jul; 2(8133):77-8. PubMed ID: 87970
[No Abstract] [Full Text] [Related]
14. The Home Infusion Therapy/Relative Benefit Index: summary of an analysis using insurance claims data.
Birnbaum HG; Tang M
Med Care; 1998 May; 36(5):757-65. PubMed ID: 9596067
[TBL] [Abstract][Full Text] [Related]
15. Cost effectiveness of haemophilia treatment: a cross-national assessment.
Lippert B; Berger K; Berntorp E; Giangrande P; van den Berg M; Schramm W; Siebert U;
Blood Coagul Fibrinolysis; 2005 Oct; 16(7):477-85. PubMed ID: 16175006
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of prophylaxis against on-demand treatment in boys with severe hemophilia A in Iran.
Daliri AA; Haghparast H; Mamikhani J
Int J Technol Assess Health Care; 2009 Oct; 25(4):584-7. PubMed ID: 19845990
[TBL] [Abstract][Full Text] [Related]
17. The economics of inpatient on-demand treatment for haemophilia with high-responding inhibitors: a US retrospective data analysis.
Pokras SM; Petrilla AA; Weatherall J; Lee WC
Haemophilia; 2012 Mar; 18(2):284-90. PubMed ID: 21812862
[TBL] [Abstract][Full Text] [Related]
18. Burden of illness: direct and indirect costs among persons with hemophilia A in the United States.
Zhou ZY; Koerper MA; Johnson KA; Riske B; Baker JR; Ullman M; Curtis RG; Poon JL; Lou M; Nichol MB
J Med Econ; 2015 Jun; 18(6):457-65. PubMed ID: 25660324
[TBL] [Abstract][Full Text] [Related]
19. An economic model of haemophilia in Mexico.
Martínez-Murillo C; Quintana S; Ambriz R; Benitez H; Berges A; Collazo J; Esparza A; Pompa T; Taboada C; Zavala S; Larochelle MR; Bentkover JD;
Haemophilia; 2004 Jan; 10(1):9-17. PubMed ID: 14962215
[TBL] [Abstract][Full Text] [Related]
20. Benefits of prophylaxis versus on-demand treatment in adolescents and adults with severe haemophilia A: the POTTER study.
Tagliaferri A; Feola G; Molinari AC; Santoro C; Rivolta GF; Cultrera DB; Gagliano F; Zanon E; Mancuso ME; Valdré L; Mameli L; Amoresano S; Mathew P; Coppola A;
Thromb Haemost; 2015 Jul; 114(1):35-45. PubMed ID: 25855376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
